

# Truman J Milling

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5070979/publications.pdf>

Version: 2024-02-01

50  
papers

3,867  
citations

331670

21  
h-index

233421

45  
g-index

52  
all docs

52  
docs citations

52  
times ranked

3714  
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding. <i>Circulation</i> , 2013, 128, 1234-1243.	1.6	706
2	Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2016, 375, 1131-1141.	27.0	692
3	Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors. <i>New England Journal of Medicine</i> , 2019, 380, 1326-1335.	27.0	687
4	Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. <i>Lancet, The</i> , 2015, 385, 2077-2087.	13.7	386
5	Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial*. <i>Critical Care Medicine</i> , 2005, 33, 1764-1769.	0.9	333
6	Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. <i>Lancet Neurology, The</i> , 2019, 18, 117-126.	10.2	159
7	Tenecteplase Thrombolysis for Acute Ischemic Stroke. <i>Stroke</i> , 2020, 51, 3440-3451.	2.0	101
8	Thromboembolic Events After Vitamin K Antagonist Reversal With 4-Factor Prothrombin Complex Concentrate: Exploratory Analyses of Two Randomized, Plasma-Controlled Studies. <i>Annals of Emergency Medicine</i> , 2016, 67, 96-105.e5.	0.6	77
9	Increased risk of volume overload with plasma compared with four-factor prothrombin complex concentrate for urgent vitamin K antagonist reversal. <i>Transfusion</i> , 2015, 55, 2722-2729.	1.6	55
10	Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase III Clinical Trials. <i>Academic Emergency Medicine</i> , 2016, 23, 466-475.	1.8	54
11	The GENESIS Project (GENERALized Early Sepsis Intervention Strategies). <i>Journal of Intensive Care Medicine</i> , 2013, 28, 355-368.	2.8	50
12	Anticoagulant Reversal Strategies in the Emergency Department Setting: Recommendations of a Multidisciplinary Expert Panel. <i>Annals of Emergency Medicine</i> , 2020, 76, 470-485.	0.6	46
13	Alcohol, bicycling, and head and brain injury: a study of impaired cyclists' riding patterns R1. <i>American Journal of Emergency Medicine</i> , 2010, 28, 68-72.	1.6	45
14	A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery. <i>Trends in Cardiovascular Medicine</i> , 2020, 30, 86-90.	4.9	37
15	Use of Ultrasonography to Identify Infants for Whom Urinary Catheterization Will Be Unsuccessful Because of Insufficient Urine Volume: Validation of the Urinary Bladder Index. <i>Annals of Emergency Medicine</i> , 2005, 45, 510-513.	0.6	29
16	Randomized Controlled Trial of Single-Operator vs. Two-Operator Ultrasound Guidance for Internal Jugular Central Venous Cannulation. <i>Academic Emergency Medicine</i> , 2006, 13, 245-247.	1.8	27
17	Prothrombin Complex Concentrates for Perioperative Vitamin K Antagonist and Non-vitamin K Anticoagulant Reversal. <i>Anesthesiology</i> , 2018, 129, 1171-1184.	2.5	27
18	Comprehensive pain management protocol reduces children's memory of pain at discharge from the pediatric ED. <i>American Journal of Emergency Medicine</i> , 2012, 30, 861-871.	1.6	26

#	ARTICLE	IF	CITATIONS
19	A review of guidelines on anticoagulation reversal across different clinical scenarios “ Is there a general consensus?. American Journal of Emergency Medicine, 2020, 38, 1890-1903.	1.6	26
20	Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy. Stroke, 2021, 52, 2096-2105.	2.0	25
21	Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents. American Journal of Medicine, 2016, 129, S80-S88.	1.5	23
22	Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation (START): Methodology of a pragmatic, response-adaptive, prospective randomized clinical trial. International Journal of Stroke, 2019, 14, 977-982.	5.9	21
23	Care plan program reduces the number of visits for challenging psychiatric patients in the ED. American Journal of Emergency Medicine, 2012, 30, 1061-1067.	1.6	20
24	Andexanet Alfa for Specific Anticoagulation Reversal in Patients with Acute Bleeding during Treatment with Edoxaban. Thrombosis and Haemostasis, 2022, 122, 998-1005.	3.4	19
25	Exploring indications for the Use of direct oral anticoagulants and the associated risks of major bleeding. American Journal of Managed Care, 2017, 23, S67-S80.	1.1	18
26	Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis. American Journal of Emergency Medicine, 2018, 36, 396-402.	1.6	17
27	Preclinical and clinical data for factor Xa and “universal” reversal agents. American Journal of Emergency Medicine, 2016, 34, 39-45.	1.6	16
28	Restart of Anticoagulant Therapy and Risk of Thrombosis, Rebleeding, and Death after Factor Xa Inhibitor Reversal in Major Bleeding Patients. Thrombosis and Haemostasis, 2021, 121, 1097-1106.	3.4	14
29	Therapeutic Hypothermia in Cocaine-Induced Cardiac Arrest. Annals of Emergency Medicine, 2008, 51, 135-137.	0.6	12
30	Human cytokine response to Texas crotaline envenomation before and after antivenom administration. American Journal of Emergency Medicine, 2010, 28, 871-879.	1.6	12
31	Restart TICrH: An Adaptive Randomized Trial of Time Intervals to Restart Direct Oral Anticoagulants after Traumatic Intracranial Hemorrhage. Journal of Neurotrauma, 2021, 38, 1791-1798.	3.4	10
32	Prospective validation of a biomarker panel to identify pediatric ED patients with abdominal pain who are at low risk for acute appendicitis. American Journal of Emergency Medicine, 2016, 34, 1373-1382.	1.6	9
33	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. American Journal of Medicine, 2016, 129, S54-S63.	1.5	9
34	Rationale and design of a statewide telestroke registry: Lone Star Stroke Consortium Telestroke Registry (LeSteR). BMJ Open, 2019, 9, e026496.	1.9	9
35	Restarting and timing of oral anticoagulation after traumatic intracranial hemorrhage: a review and summary of ongoing and planned prospective randomized clinical trials. Trauma Surgery and Acute Care Open, 2020, 5, e000605.	1.6	9
36	Heparin-Induced Thrombocytopenia Associated with Massive Intracardiac Thrombosis: A Case Report. Case Reports in Hematology, 2012, 2012, 1-4.	0.4	8

#	ARTICLE	IF	CITATIONS
37	Four-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding: A Post Hoc Analysis of Two Randomized Controlled Trials. <i>Emergency Medicine International</i> , 2017, 2017, 1-8.	0.8	8
38	Anticoagulant Reversal in Gastrointestinal Bleeding: Review of Treatment Guidelines. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3698-3714.	2.3	8
39	Atypical presentation of fatal meningococemia: peritonitis and paradoxical centrifugal purpura fulminans of late onset. <i>American Journal of Emergency Medicine</i> , 2011, 29, 960.e3-960.e5.	1.6	7
40	Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review. <i>Annals of Emergency Medicine</i> , 2017, 69, 531-540.	0.6	7
41	Randomized Phase IIIb Study Of Rapid Vitamin K Antagonist Reversal In Patients Requiring An Urgent Surgical Procedure: Four-Factor Prothrombin Complex Concentrate Is Superior To Plasma. <i>Blood</i> , 2013, 122, 3588-3588.	1.4	7
42	Shock, respiratory failure, and coagulopathy after an intravenous copperhead envenomation. <i>American Journal of Emergency Medicine</i> , 2009, 27, 377.e1-377.e5.	1.6	6
43	Low-dose versus standard-dose four-factor prothrombin complex concentrate for factor Xa inhibitor reversal in spontaneous and traumatic intracranial hemorrhage. <i>Pharmacotherapy</i> , 2021, 41, 501-507.	2.6	6
44	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <i>American Journal of Emergency Medicine</i> , 2016, 34, 19-25.	1.6	3
45	The authors reply: alcohol, helmets and head injury. <i>American Journal of Emergency Medicine</i> , 2010, 28, 528-529.	1.6	1
46	617: MANAGEMENT STRATEGIES OF PATIENTS RECEIVING FXA INHIBITORS OR LMWH ADMITTED FOR ICH. <i>Critical Care Medicine</i> , 2016, 44, 230-230.	0.9	0
47	1708: EMERGENT REVERSAL OF APIXABAN WITH ANDEXANET ALFA TO FACILITATE DEBRIDEMENT OF NECROTIZING FASCIITIS. <i>Critical Care Medicine</i> , 2016, 44, 502-502.	0.9	0
48	Andexanet Response. <i>Annals of Emergency Medicine</i> , 2019, 74, 724-725.	0.6	0
49	4-Factor Prothrombin Complex Concentrate Reduces Time to Procedure in Vitamin K Antagonist-Treated Patients Experiencing Gastrointestinal Bleeding. <i>American Journal of Gastroenterology</i> , 2016, 111, S402-S403.	0.4	0
50	Celebrating <i>Annals of Emergency Medicine's</i> 50th Anniversary. <i>Annals of Emergency Medicine</i> , 2022, 79, 1.	0.6	0